
Samsung Bioepis projects $580 mil. in EU cost savings as Stelara biosimilar gains ground
With patent walls down on the blockbuster immunology drug Stelara, Samsung Bioepis is making its move. Backed by a courtroom win in Europe and new budget impact data, the Korean biosimilar maker is projecting more than €526 million ($580 million) in cost …